FMPV 2
Alternative Names: FMPV-2Latest Information Update: 28 Apr 2026
At a glance
- Originator Hubro Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Endometrial cancer
- No development reported Colorectal cancer
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for research development in Colorectal-cancer in Norway (Parenteral)
- 28 Apr 2026 No recent reports of development identified for research development in Colorectal-cancer(Prevention) in Norway (Parenteral)
- 12 Dec 2022 Preclinical trials in Endometrial cancer (Prevention) in Norway (Parenteral) (Hubro Therapeutics pipeline, December 2022)